A team of researchers has developed a new platform technology that uses red blood cells to generate targeted immune responses in mice. Researchers have noticed that the new technology has successfully slowed the growth of cancerous tumors in mice, and could also be used as a biocompatible adjuvant in a different type of vaccine. The research paves the way to an exciting array of future developments in the field of using human cells for disease treatment and prevention. The study is an inspiring step forward toward that goal, and could dramatically change how immune responses are changed in patients.